NEW YORK ( TheStreet) -- Shares of Zalicus (Nasdaq: ZLCS) were gapping down Monday morning with an open price 15.5% lower than Friday's closing price. The stock closed at $1.61 Friday and opened today's trading at $1.36. The average volume for Zalicus has been 1.7 million shares per day over the past 30 days. Zalicus has a market cap of $191.8 million and is part of the health care sector and drugs industry. Shares are up 1.9% year to date as of the close of trading on Friday. Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of drug candidates focusing on the treatment of pain and inflammation. TheStreet Ratings rates Zalicus as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. You can view the full Zalicus Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.
Zalicus (ZLCS) soared Wednesday after the biopharmaceutical company announced it would merge with Epirus Biopharmaceuticals. After the all-stock transaction closes, Zalicus will be known as Epirus and will operate under the latter company's management team led by Amit Munshi as president and CEO. Current Zalicus stockholders will own approximately 19% of the company. The merger will create a publicly-traded company listed on the NASDAQ.